E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
NON−SMALL CELL LUNG CANCER |
|
E.1.1.1 | Medical condition in easily understood language |
NON−SMALL CELL LUNG CANCER |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029514 |
E.1.2 | Term | Non-small cell lung cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of 16 cycles of atezolizumab treatment compared with best supportive care as measured by disease-free survival (DFS) as assessed by the investigator.
|
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of 16 cycles of atezolizumab treatment compared with BSC as measured by OS |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Tumor PD-L1 expression of TC3 or IC3, as determined by an IHC assay performed by a central laboratory on a resected tumor tissue previously obtained at screening. A representative formalin-fixed paraffin-embedded (FFPE) tumor specimen in paraffin block (preferred) or a minimum of 15 unstained, freshly cut, serial sections from an FFPE resected tumor specimen is required for participation in
this study. This specimen must be accompanied by the associated pathology report.
•ECOG performance status of 0 or 1
•Histological or cytological diagnosis of Stage IB (tumors ≥ 4 cm)−IIIA (T2−3 N0, T1−3 N1, T1-3 N2) NSCLC
•Eligibility to receive a cisplatin-based chemotherapy regimen
•For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of study drug |
|
E.4 | Principal exclusion criteria |
• Pregnant and lactating women
•Treatment with prior systemic chemotherapy at any time
Methotrexate given in low doses for non-malignant conditions with the last dose
at least 14 days prior to date of enrollment will be allowed. Other low-dose
chemotherapeutics for non-malignant conditions will be considered after
discussion with and approval by the Medical Monitor
•Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years before enrollment
•Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrollment
•Known sensitivity to any component of the chemotherapy regimen the patient will be assigned to, or to mannitol
•Prior treatment with an anti−PD-1, anti−PD-L1, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
•DFS, defined as the time from randomization to the date of occurrence of any of the following, whichever occurs first:
First recurrence of NSCLC, as determined by the investigator after an
integrated assessment of radiographic data, biopsy sample results (if available),
and clinical status
Occurrence of new primary NSCLC, as assessed by the investigator
Death from any cause |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•OS, defined as the time from randomization to death from any cause |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 119 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Canada |
China |
France |
Germany |
Hong Kong |
Hungary |
Israel |
Italy |
Japan |
Korea, Republic of |
Netherlands |
Poland |
Portugal |
Romania |
Russian Federation |
Spain |
Taiwan |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the latter of the dates of when 433 deaths have occurred in the global main study’s ITT population and 355 deaths have occurred in the Stage II−IIIA subpopulation. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |